Stopping GLP-1s May Trigger Weight Regain and Heart Risk
Reports suggest discontinuing GLP-1 medications (like semaglutide/tirzepatide) often leads to meaningful weight regain and may worsen cardiometabolic risk facto...
Weight regain is a critical topic as millions begin GLP-1 medications like semaglutide and tirzepatide, only to face potential stop-start cycles due to insurance limitations. Reports highlight that discontinuing these drugs often leads to significant weight regain and may worsen cardiometabolic risks. For content creators, this offers a timely angle to explore the challenges of long-term weight management and the broader health implications tied to these widely used medications.
Reports suggest discontinuing GLP-1 medications (like semaglutide/tirzepatide) often leads to meaningful weight regain and may worsen cardiometabolic risk facto...
Quitting GLP-1s isn’t just “stopping a med.” For many, appetite returns + weight regain follows. The real question: what’s your maintenance plan (training, protein, follow-ups) BEFORE you stop?
Hot take: Obesity care keeps failing because we treat it like a 12-week project instead of a chronic condition.